Comparative Pharmacology
Head-to-head clinical analysis: AMPICILLIN TRIHYDRATE versus VEETIDS 125.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMPICILLIN TRIHYDRATE versus VEETIDS 125.
AMPICILLIN TRIHYDRATE vs VEETIDS '125'
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and autolysin activity.
VEETIDS '125' (presumed to be a formulation containing penicillin V potassium) inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and activating autolytic enzymes.
250-500 mg PO q6h or 1-2 g IV/IM q4-6h; up to 12 g/day IV for severe infections.
125 mg orally twice daily for 5-10 days.
None Documented
None Documented
Terminal elimination half-life 1-1.8 hours; prolonged in renal impairment (up to 10-20 hours in anuria)
2-4 hours in patients with normal renal function (CrCl >80 mL/min); prolonged to 20-40 hours in anuria. Clinical note: dosing interval must be adjusted based on creatinine clearance to avoid accumulation.
Renal: 75-90% unchanged; biliary: small amount; fecal: negligible
Primarily renal (80-90% unchanged) via glomerular filtration and tubular secretion; biliary/fecal <5%.
Category A/B
Category C
Penicillin Antibiotic
Penicillin Antibiotic